Futura Medical Asset Resilience Ratio
Futura Medical asset resilience ratio. Futura Medical (FUM) has an Asset Resilience Ratio of 23.08% as of December 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Futura Medical fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Futura Medical (2016–2020)
Asset resilience ratio of Futura Medical from 2016 to 2020. This chart shows how Futura Medical's Asset Resilience Ratio has changed over time. Read total liabilities of Futura Medical for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Futura Medical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Futura Medical.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX373.87K | 23.08% |
| Total Liquid Assets | GBX373.87K | 23.08% |
Asset Resilience Insights
- Good Liquidity Position: Futura Medical maintains a healthy 23.08% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Futura Medical Industry Peers by Asset Resilience Ratio
Compare Futura Medical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Futura Medical Asset Resilience Ratio by Year (2016–2020)
Futura Medical asset resilience ratio by year from 2016 to 2020. The table below shows the annual Asset Resilience Ratio data for Futura Medical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 23.08% | GBX373.87K ≈ $45.49 |
GBX1.62 Million ≈ $197.12 |
+15.47pp |
| 2019-12-31 | 7.61% | GBX372.90K ≈ $45.37 |
GBX4.90 Million ≈ $596.33 |
-24.12pp |
| 2018-12-31 | 31.73% | GBX3.45 Million ≈ $419.94 |
GBX10.88 Million ≈ $1.32K |
-53.58pp |
| 2017-12-31 | 85.31% | GBX8.19 Million ≈ $996.95 |
GBX9.60 Million ≈ $1.17K |
-5.51pp |
| 2016-12-31 | 90.82% | GBX12.21 Million ≈ $1.49K |
GBX13.44 Million ≈ $1.64K |
-- |
About Futura Medical
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Fut… Read more